Skip to content

Last week in biopharma partnering: May 1- 7, 2022

By pharma3dadmin May 9, 2022

Each week (well almost, some weeks are quite uneventful), we compile and curate hot-off-the-press news and updates on the happenings in the world of pharma and life sciences partnering.

Be sure to follow us and keep up-to-date on all things partnering to inform your decisions and strategies.

Gilead Sciences signs deal with Dragonfly Therapeutics for natural killer (NK) cell category, paying $300 million upfront to access TriNKET platform — see full article.

Byondis B.V., a Dutch clinical stage biopharmaceutical company, has signed a License and Collaboration Agreement and a Supply Agreement with medac GmbHsee full article.

Protagonist presents Q1 2022 financial results and shares topline results from the Phase 2 IDEAL study of PN-943 in ulcerative colitis — see full article.

Alcami, a US-based CDMO and Civica Inc., a nonprofit pharma, enter into multi-year partnering agreement — see full article.

Jazz and Sumitomo Pharma enter into exclusive license agreement to develop and commercialize sleep disorder therapies — see full article.

Illumina, Inc., a DNA sequencing and array-based technologies company, and Deerfield Management announced a five-year partnership to focus on genetic-led drug discovery and development — see full article.